Black Diamond Therapeutics (BDTX) News Today $1.69 +0.01 (+0.60%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.30%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With ServierMarch 25 at 2:00 AM | seekingalpha.comWedbush Analysts Boost Earnings Estimates for BDTXMarch 25 at 1:31 AM | americanbankingnews.comWhat is Wedbush's Estimate for BDTX Q1 Earnings?Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush upped their Q1 2025 earnings estimates for shares of Black Diamond Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Wedbush analyst R. Driscoll now forecasts tMarch 24 at 1:32 AM | marketbeat.comHC Wainwright Issues Pessimistic Outlook for BDTX EarningsMarch 22 at 1:41 AM | americanbankingnews.comGrowth N. V. Biotech Sells 5,784,292 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) StockBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now directly owns 2,733,547 shares of the company's stock, valued at $5,658,442.29. This represents a 67.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 21, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)March 21, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for BDTX Q1 Earnings?Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2025 EPS estimates for Black Diamond Therapeutics in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.March 21, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Major Shareholder Sells $11,973,484.44 in StockMarch 21, 2025 | insidertrades.comBlack Diamond Therapeutics (NASDAQ:BDTX) Earns "Outperform" Rating from WedbushMarch 21, 2025 | americanbankingnews.comPenny Stocks To Follow Now - March 19thBlack Diamond Therapeutics, Aterian, and Plug Power are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced equity shares, usually trading for less than $5 per share, often issued by small, less-established companies. They tend to be higMarch 20, 2025 | marketbeat.comServier and Black Diamond sign deal for solid tumours therapyMarch 20, 2025 | finance.yahoo.comBlack Diamond Therapeutics (NASDAQ:BDTX) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.March 20, 2025 | marketbeat.comBlack Diamond Therapeutics Sees Unusually High Options Volume (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 1,853 call options on the stock. This represents an increase of approximately 1,419% compared to the typical volume of 122 call options.March 20, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Black Diamond Therapeutics (NASDAQ:BDTX) StockMarch 20, 2025 | americanbankingnews.comBlack Diamond, Servier announce global licensing agreement for BDTX-4933March 19, 2025 | markets.businessinsider.comBlack Diamond stock soars on licensing dealMarch 19, 2025 | in.investing.comBlack Diamond Therapeutics Shares Surge on Servier Licensing DealMarch 19, 2025 | marketwatch.comThis Biotech Is Finding Mid-Week Success Following Licensing Agreement AnnouncementMarch 19, 2025 | msn.comBlack Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 MillionMarch 19, 2025 | benzinga.comBlack Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-HighMarch 19, 2025 | msn.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Raised to $12.00HC Wainwright increased their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday.March 19, 2025 | marketbeat.comServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyMarch 19, 2025 | tmcnet.comServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyMarch 19, 2025 | globenewswire.comBlack Diamond price target raised to $12 from $11 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comBlack Diamond Therapeutics: In Decline, But Why?March 13, 2025 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Revelation Biosciences (REVB)March 10, 2025 | markets.businessinsider.comBrokers Issue Forecasts for BDTX Q1 EarningsBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Investment analysts at Wedbush issued their Q1 2026 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Friday, March 7th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.22) pMarch 10, 2025 | marketbeat.comBlack Diamond Therapeutics Q4 Loss Decreases, Beats EstimatesMarch 8, 2025 | nasdaq.comBlack Diamond Therapeutics (NASDAQ:BDTX) Price Target Cut to $15.00 by Analysts at Stifel NicolausStifel Nicolaus dropped their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday.March 8, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Black Diamond Therapeutics (NASDAQ:BDTX)Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price (down from $16.00) on shares of Black Diamond Therapeutics in a research note on Friday.March 8, 2025 | marketbeat.comBlack Diamond Therapeutics Reports 2024 Financial ResultsMarch 7, 2025 | tipranks.comBlack Diamond Therapeutics (NASDAQ:BDTX) Issues Earnings ResultsBlack Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03.March 7, 2025 | marketbeat.comBlack Diamond Therapeutics price target lowered to $15 from $16 at StifelMarch 7, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)March 7, 2025 | markets.businessinsider.comBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comBlack Diamond Therapeutics (BDTX) Expected to Announce Earnings on TuesdayBlack Diamond Therapeutics (NASDAQ:BDTX) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.March 4, 2025 | marketbeat.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Declines By 5.9%Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 7,050,000 shares, a drop of 5.9% from the January 15th total of 7,490,000 shares. Based on an average daily volume of 761,200 shares, the short-interest ratio is currently 9.3 days.February 18, 2025 | marketbeat.comBlack Diamond Therapeutics, Inc. Common Stock (BDTX) Analyst ResearchFebruary 2, 2025 | nasdaq.comShort Interest in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Expands By 17.8%Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 7,490,000 shares, an increase of 17.8% from the December 31st total of 6,360,000 shares. Based on an average daily trading volume, of 769,500 shares, the days-to-cover ratio is currently 9.7 days.February 1, 2025 | marketbeat.comBlack Diamond Therapeutics: Speculative Buy With Precision Oncology CatalystsDecember 30, 2024 | seekingalpha.comPoint72 Asset Management L.P. Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Point72 Asset Management L.P. bought a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 697,125 shares of the companDecember 10, 2024 | marketbeat.comVestal Point Capital LP Grows Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Vestal Point Capital LP grew its holdings in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 139.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,028,500 shares of the company's stocNovember 29, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 13.5% in OctoberBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 6,330,000 shares, a drop of 13.5% from the October 15th total of 7,320,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is presently 5.2 days.November 16, 2024 | marketbeat.comFY2024 Earnings Estimate for BDTX Issued By HC WainwrightBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Investment analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Tuesday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company wiNovember 8, 2024 | marketbeat.comWedbush Has Positive Outlook of BDTX FY2024 EarningsBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush lifted their FY2024 EPS estimates for Black Diamond Therapeutics in a note issued to investors on Tuesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings perNovember 8, 2024 | marketbeat.comBlack Diamond Therapeutics Reports Promising Q3 2024 ResultsNovember 7, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comStrong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical DevelopmentsNovember 5, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond TherapeuticsNovember 5, 2024 | markets.businessinsider.comBlack Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 5, 2024 | globenewswire.com Remove Ads Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDTX Media Mentions By Week BDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDTX News Sentiment▼0.760.68▲Average Medical News Sentiment BDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDTX Articles This Week▼322▲BDTX Articles Average Week Remove Ads Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RAPP News Today SLDB News Today HRTX News Today ALLO News Today ARCT News Today ATXS News Today GLUE News Today CYRX News Today AURA News Today ESPR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
